Lidds: Next step for docetaxel candidate - Redeye

Redeye sees increased pipeline value in a prospective validation of the efficacy of LIDDS' drug candidate with docetaxel. Documented efficacy, especially in combination with immunotherapies, is an important basis for attracting and negotiating with prospective licensing partners.

Länk till analysen i sin helhet: https://www.redeye.se/research/833963/lidds-next-stage-for-docetaxel-candidate?utm_source=finwire&utm_medium=RSS